Happy Monday, readers. I hope you had a wonderful weekend.
I'm about to board a flight, so I'm afraid we'll have to keep it short this evening. That's not to say there's no news around there (hey, in this space, there always is).
Consider: CVS is rolling out an Amazon-style delivery system (the CarePass program telegraphed last year) for the big old price of $48 per year. That's a service that will give customers access to a variety of CVS services, including in the pharmacy and discounts to CVS-branded items.
Back with more tomorrow.
Guardant’s cancer blood test could boost certain drug makers. This is one of those “in-the-weeds” kind of things – but it’s an important one to traverse. Guardant Health, a company focused on creating blood tests that could potentially replace invasive biopsies, reached a milestone in the immunotherapy space that could potentially become a milestone in the firm’s efforts. Specifically, Guardant’s blood test could help determine whether or not certain cancer patients may be suitable for cancer immunotherapies such as Merck’s Keytruda. (Endpoints News)
THE BIG PICTURE
America’s gun violence epidemic. I’ve written about it. My colleagues have written about it. It’s really no secret. The United States is exceptional (in a tragic way) when it comes to gun violence and associated deaths. The two mass shootings in Texas and Ohio over this past weekend add to the unfortunate numbers. According to TIME, there have been 62 people killed in mass shootings in the U.S. this year alone.
China’s Biggest Private Sector Company Is Betting Its Future on Data, by Clay Chandler
Here’s Why Tech Stocks Are Seeing Big Selloffs Today, by Kevin Kelleher
Behind China’s ‘Momentous’ Decision to Weaponize the Yuan, by Erik Sherman
Find past coverage. Sign up for other Fortune newsletters.